Trial intelligence / Profile preview

Duvakitug maintenance study in moderately to severely active ulcerative colitis

2025-521038-27-00Phase 3Authorised

Sponsor: Sanofi
Start: Jun 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 39

Overview

Phase 3, randomised, double-blind trial of duvakitug in autoimmune colitis (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission by modified Mayo Score. Planned start Jun 2026; status: authorised.

Drugs

duvakitug

Conditions

autoimmune colitis

Beyond the preview

Go deeper on 2025-521038-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-521038-27-00.